Literature DB >> 29845281

miR‑205 targets YAP1 and inhibits proliferation and invasion in thyroid cancer cells.

Dewei Li1, Qiang Wang2, Ning Li3, Shuilong Zhang2.   

Abstract

MicroRNA‑205 (miR‑205) has been reported to be downregulated, and serves critical roles in the pathogenesis and progression of several types of cancer, including breast, prostate and lung cancer. However, the underlying mechanism of miR‑205 in thyroid cancer remains unclear. In the present study, it was demonstrated that the expression of miR‑205 was reduced in thyroid cancer tissues compared with non‑cancer tissues. In addition, miR‑205‑knockdown models in the BHT‑101 cell line and ectopic expression models in the 8505‑C cell line were used to measure the biological functions of miR‑205. The results indicated that miR‑205 inhibited certain aspects of thyroid cancer, including cell proliferation, migration and invasion. Furthermore, Yes‑associated protein 1 (YAP1) was identified as a target gene of miR‑205 and its expression was negatively correlated with that of miR‑205 in thyroid cancer tissues. Depletion of YAP1 partially reduced the anti‑miR‑205‑induced cell growth and invasion. The results of the present study suggested that the tumor suppressive functions of miR‑205 via targeting YAP1 could be a novel target for the treatment of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29845281     DOI: 10.3892/mmr.2018.9074

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

1.  Targeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study.

Authors:  Liwen Guo; Jiaping Zheng; Jun Luo; Zhewei Zhang; Guoliang Shao
Journal:  Onco Targets Ther       Date:  2020-10-29       Impact factor: 4.147

Review 2.  MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer.

Authors:  Amir Abbas Hamidi; Negin Taghehchian; Zahra Basirat; Amir Sadra Zangouei; Meysam Moghbeli
Journal:  Biomark Res       Date:  2022-06-04

3.  microRNA-205 and microRNA-338-3p Reduces Cell Apoptosis in Prostate Carcinoma Tissue and LNCaP Prostate Carcinoma Cells by Directly Targeting the B-Cell Lymphoma 2 (Bcl-2) Gene.

Authors:  Xi Zhang; Yuliang Pan; Huiqun Fu; Juan Zhang
Journal:  Med Sci Monit       Date:  2019-02-11

Review 4.  Targeting the Hippo Pathway in Prostate Cancer: What's New?

Authors:  Kelly Coffey
Journal:  Cancers (Basel)       Date:  2021-02-04       Impact factor: 6.575

5.  Evaluation of Diagnostic Potential of Epigenetically Deregulated MiRNAs in Epithelial Ovarian Cancer.

Authors:  Vivek Kumar; Sameer Gupta; Amrita Chaurasia; Manisha Sachan
Journal:  Front Oncol       Date:  2021-10-07       Impact factor: 6.244

Review 6.  MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Authors:  Maria Papaioannou; Angeliki G Chorti; Anthoula Chatzikyriakidou; Kleanthis Giannoulis; Sohail Bakkar; Theodosios S Papavramidis
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

7.  MiR-205-5p/GGCT Attenuates Growth and Metastasis of Papillary Thyroid Cancer by Regulating CD44.

Authors:  Han-Ning Li; Hui-Min Zhang; Xing-Rui Li; Jun Wang; Tao Xu; Shu-Yu Li; Meng-Lu Dong; Ge Wang; Xiao-Qing Cui; Xue Yang; Yong-Lin Wu; Xing-Hua Liao; Ya-Ying Du
Journal:  Endocrinology       Date:  2022-04-01       Impact factor: 4.736

8.  Circular RNA_0057209 Acts as ceRNA to Inhibit Thyroid Cancer Progression by Promoting the STK4-Mediated Hippo Pathway via Sponging MicroRNA-183.

Authors:  Xinzhi Peng; Yue Zhu; Shaojian Lin; Weiming Yu; Cheng Zhang; Langping Tan; Miaoyun Long; Dingyuan Luo; Chengcheng Ji
Journal:  Oxid Med Cell Longev       Date:  2022-03-11       Impact factor: 6.543

9.  Immortalization up-regulated protein promotes tumorigenesis and inhibits apoptosis of papillary thyroid cancer.

Authors:  Lizhi Lin; Jialiang Wen; Bangyi Lin; Adheesh Bhandari; Danni Zheng; Lingguo Kong; Yinghao Wang; Ouchen Wang; Yizuo Chen
Journal:  J Cell Mol Med       Date:  2020-10-23       Impact factor: 5.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.